贫血是慢性心力衰竭患者非常常见的并发症,它与慢性心力衰竭疗效、再住院率、病死率等预后密切相关.促红细胞生成素治疗合并贫血的慢性心力衰竭患者,可显著改善心功能、临床症状及提高生活质量,但促红细胞生成素在治疗过程中可能出现血压升高、血栓形成、癫痫发作等不良反应.就目前的临床研究表明促红细胞生成素治疗慢性心力衰竭是安全的.现就促红细胞生成素在慢性心力衰竭中的临床应用做一综述.“,”Anemia is a very common complication in patients with chronic heart failure(CHF).It is closely related with the prognosis of CHF,such as the effect of the treatment,the rate of re-hospitalization and mortality.The use of erythropoietin (EPO) in patients with chronic heart failure patients with anemia,can significantly improve the cardiac function,clinical symptoms and the quality of life,however EPO may elevate blood pressure,thrombosis,seizures and other side effects in the treatment process.The cmrent clinical research shows that the use of EPO in the treatment of CHF is safe,This article reviews the clinical application of EPO in CHF.